AHRQ Patient Safety Network ► FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam).

AHRQ Patient Safety Network



FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam).

FDA Safety Communication. Silver Spring, MD: US Food and Drug Administration; May 20, 2015.

Dosing information on drug labels should be clearly articulated to prevent confusion. This announcement raises awareness of a drug strength labeling change regarding active ingredients in the antibacterial drug Zerbaxa to improve dosing accuracy.

Free full text 

Related Resources

NEWSPAPER/MAGAZINE ARTICLE

Side tracks on the safety express. Interruptions lead to errors and unfinished…wait, what was I doing?

ISMP Medication Safety Alert! Acute Care Edition. November 29, 2012;17:1-3.

COMMENTARY

Failure to Report

Spath PL. AHRQ WebM&M [serial online]. March 2007.

STUDY

Reducing warfarin medication interactions: an interrupted time series evaluation.

Feldstein AC, Smith DH, Perrin N, et al. Arch Intern Med. 2006;166:1009-1015.

NEWSPAPER/MAGAZINE ARTICLE

Medication errors occurring with the use of bar-code administration technology.

PA-PSRS Patient Saf Advis. December 2008;5:122-126.

View all related resources...